Symbol="PRLD"
AssetType="Common Stock"
Name="Prelude TherapeuticsÂ Inc"
Description="Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware."
CIK="1678660"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="200 POWDER MILL ROAD, WILMINGTON, DE, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="206629000"
EBITDA="-124046000"
PERatio="None"
PEGRatio="None"
BookValue="4.788"
DividendPerShare="0"
DividendYield="0"
EPS="-2.59"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.29"
ReturnOnEquityTTM="-0.464"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-2.59"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="9.4"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.145"
EVToRevenue="-"
EVToEBITDA="-0.214"
Beta="0.328"
num_52WeekHigh="8.66"
num_52WeekLow="3.17"
num_50DayMovingAverage="4.21"
num_200DayMovingAverage="5.67"
SharesOutstanding="41958500"
DividendDate="None"
ExDividendDate="None"
symbol="PRLD"
open="3.87"
high="4.07"
low="3.78"
price="4.02"
volume="51685.00"
latest_trading_day="2023-08-28"
previous_close="3.77"
change="0.25"
change_percent="6.6313%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="70"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="30"
Volume_recent_avg="113729"
Change_recent_avg="-0.01"
Delta_recent_avg="0.41"
Variance_recent_avg="0.21"
Change_ratio_recent_avg="-0.42"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="30"
Aroon_momentum_negative="70"
image_negative_thumbnail_id_1="154"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0022.jpeg"
image_negative_thumbnail_id_2="133"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0043.jpeg"
image_neutral_thumbnail_id_1="559"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0040.jpeg"
image_neutral_thumbnail_id_2="552"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0047.jpeg"
image_positive_thumbnail_id_1="681"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0027.jpeg"
image_positive_thumbnail_id_2="605"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0103.jpeg"
image_professor_thumbnail_id_1="1169"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0003.jpeg"
image_professor_thumbnail_id_2="1186"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0020.jpeg"
